$OFIX

Orthofix Medical Inc.

Orthofix is a global medical technology company headquartered in Lewisville, Texas. It provides medical technologies for musculoskeletal conditions, including spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies. Orthofix operates two reporting segments, Global Spine and Global Limb Reconstruction. Global Spine offers implantable devices, biologics, navigation technologies and other regenerative solutions for patients with spinal diseases and injuries. Its products include spinal fixation implants, bone graft substitutes, bone growth stimulation devices such as SpinalStim and CervicalStim, and the 7D FLASH Navigation System. Global Limb Reconstruction designs and markets external and internal fixation products and digital technologies for deformity correction, limb lengthening, complex fracture management and limb preservation. Orthofix sells products through distributors and sales representatives, and also receives marketing fees through its collaboration with MTF for certain tissue products.

1
0
1
$5.1M
$1K
Juniper Investment Company, LLC
33%
See all $OFIX insider activity →
High

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

OFIX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OFIX (Orthofix Medical Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent OFIX coverage spans earnings, insider activity and financial news.

In the last 30 days, OFIX insiders filed 3 SEC Form 4 transactions — 2 purchases ($5.1M) and 1 sale ($1K). The most active reporter was Juniper Investment Company, LLC with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving OFIX

AlphAI scores every news story that mentions OFIX with an AI model for sentiment and relevance, and aggregates insider trades from Orthofix Medical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $OFIX

Score
$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

TD Cowen cuts Orthofix Medical stock price target on supply issues

TD Cowen reduced its price target for Orthofix Medical (OFIX) to $9 from $12, citing Q3 results that missed expectations and supply issues. The stock has fallen 48% year-to-date. OFIX revised its 2026 guidance lower due to Q4 challenges. Despite a Q3 earnings beat, revenue missed forecasts, leading to a negative market reaction. Analysts expect profitability in 2024 with earnings of $0.69 per share.

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMedEarnings

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte

Orthofix (OFIX) Q2 2026 Earnings Call Transcript

Orthofix (OFIX) reported Q2 2026 pro forma constant-currency net sales growth of 5% year over year, with double-digit growth in Global Limb Reconstruction and Spine Fixation. Biologics net sales were about flat after prior declines. Therapeutic Solutions grew 3% despite Medicare reimbursement pressure, but CMS restored reimbursement for bone growth stimulators. Orthofix plans a Q4 launch of its VIRATA spinal implant system.

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.

Related tickers